Minovar announced that the dagliflozin API from Xuancheng Menohua Pharmaceutical Co., Ltd., a wholly-owned subsidiary, passed the technical review by the Drug Evaluation Center of the State Drug Administration, and the registration number changed to “A” status. The drug is indicated for improving blood sugar control in adult patients with type 2 diabetes, reducing glucose reabsorption by inhibiting SGLT2, and increasing urinary sugar excretion.
美诺华：全资子公司达格列净原料药通过CDE技术审评
Minovar: Wholly-owned subsidiary dapagliflozin API passed CDE technical review
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.